Incyte (INCY) Capital Expenditures Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.66% |
| Dec 31, 2025 | 40.56% |
| Sep 30, 2025 | 15.51% |
| Jun 30, 2025 | 15.28% |
| Mar 31, 2025 | -39.55% |
| Dec 31, 2024 | 51.76% |
| Sep 30, 2024 | 16.68% |
| Jun 30, 2024 | -61.18% |
| Mar 31, 2024 | -53.84% |
| Dec 31, 2023 | 22.88% |
| Sep 30, 2023 | -22.64% |
| Jun 30, 2023 | -7.43% |
| Mar 31, 2023 | -1.11% |
| Dec 31, 2022 | -20.39% |
| Sep 30, 2022 | 21.83% |
| Jun 30, 2022 | -15.70% |
| Mar 31, 2022 | -5.54% |
| Dec 31, 2021 | -99.83% |
| Sep 30, 2021 | 19.12% |
| Jun 30, 2021 | 2.52% |
| Mar 31, 2021 | 30.76% |
| Dec 31, 2020 | 7.65% |
| Sep 30, 2020 | -16.52% |
| Jun 30, 2020 | -67.37% |
| Mar 31, 2020 | 61.69% |
| Dec 31, 2019 | -104.71% |
| Sep 30, 2019 | -25.30% |
| Jun 30, 2019 | 40.30% |
| Mar 31, 2019 | 46.98% |
| Dec 31, 2018 | -34.36% |
| Sep 30, 2018 | 99.32% |
| Jun 30, 2018 | 81.16% |
| Mar 31, 2018 | 69.72% |
| Dec 31, 2017 | 154.99% |
| Sep 30, 2017 | -152.30% |
| Jun 30, 2017 | 97.81% |
| Mar 31, 2017 | 111.45% |
| Dec 31, 2016 | 32.16% |
| Sep 30, 2016 | -134.20% |
| Jun 30, 2016 | 138.07% |
| Mar 31, 2016 | 58.73% |
| Dec 31, 2015 | 20.28% |
| Sep 30, 2015 | 95.65% |
| Jun 30, 2015 | 29.71% |
| Mar 31, 2015 | 63.30% |